Jaguar Animal Health Company Profile (NASDAQ:JAGX)

Analyst Ratings

Consensus Ratings for Jaguar Animal Health (NASDAQ:JAGX) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00 (420.83% upside)

Analysts' Ratings History for Jaguar Animal Health (NASDAQ:JAGX)
Show:
DateFirmActionRatingPrice TargetActions
6/13/2016AegisReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/30/2016Feltl & Co.DowngradeStrong-Buy -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Jaguar Animal Health (NASDAQ:JAGX)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Jaguar Animal Health (NASDAQ:JAGX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.49)($0.49)($0.49)
Q2 20161($0.45)($0.45)($0.45)
Q3 20161($0.46)($0.46)($0.46)
Q4 20161($0.40)($0.40)($0.40)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Jaguar Animal Health (NASDAQ:JAGX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Jaguar Animal Health (NASDAQ:JAGX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/8/2016James J BochnowskiDirectorBuy160,000$2.50$400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Jaguar Animal Health (NASDAQ:JAGX)
DateHeadline
07/25/16 04:51 PMJaguar Animal Health (JAGX) Announces Positive Topline Results of Two Studies to Evaluate Neonorm in Piglets
07/25/16 09:16 AMJaguar Animal Health Announces Positive Preliminary Topline Results of Two Chinese-sponsored Farm Studies …
07/25/16 08:28 AMJaguar Animal Health Announces Positive Preliminary Topline Results of Two Chinese-sponsored Farm Studies to Evaluate the Safety and Effectiveness of Neonorm Botanical Extract in Piglets - [at noodls] - SAN FRANCISCO, July 25, 2016 /PRNewswire/ -- Jaguar Animal Health, Inc. (NASDAQ: JAGX) ('Jaguar' or the 'Company'), an animal health company focused on developing and commercializing first-in-class gastrointestinal ...
07/02/16 07:37 AM7 reasons why Cambridge is the geek capital of the UK
06/30/16 04:59 PMJaguar Animal Health (JAGX) Names New Chief Scientific Officer
06/30/16 08:21 AMJaguar Animal Health Appoints Leading Oncologist and Drug Development Executive as Chief Scientific Officer - [at noodls] - Dr. Roger Waltzman to Lead Development Teams for Jaguar's SB-300 and Canalevia Drug Product Candidates SAN FRANCISCO--(BUSINESS WIRE)--Jun. 30, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) ('Jaguar' ...
06/21/16 04:27 PMJAGUAR ANIMAL HEALTH, INC. : Change in Directors or Principal Officers (form 8-K)
06/21/16 12:19 PMJAGUAR ANIMAL HEALTH, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
06/20/16 09:32 AMJAGUAR ANIMAL HEALTH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a -
06/18/16 04:13 PMJaguar (JAGX) Announces Positive Topline Results for Second-Gen Formulation of Neonorm Calf; Offers Commercialization Strategy Updates
06/17/16 04:36 PMJaguar's Neonorm shows positive effect in preventing diarrhea in dairy calves; shares up 20%
06/17/16 04:36 PMJaguar Animal Health Announces Positive Topline Results of …
06/17/16 01:19 PMJaguar Animal Health Announces Positive Topline Results of University Study of Second-Generation Formulation of Neonorm Calf and Commercialization Strategy Updates - [at noodls] - Advances commercialization strategy for equine and companion animal drug product candidates SAN FRANCISCO--(BUSINESS WIRE)--Jun. 17, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company'), ...
06/17/16 08:04 AM9:04 am Jaguar Animal Health announces topline results from study conducted in conjunction with researchers from Cornell University College of Veterinary Medicine to evaluate safety/efficacy of prophylactic use of second-gen powder formulat -
06/11/16 04:50 PMJaguar Animal Health, Inc. (JAGX) Updated Broker Ratings
06/10/16 04:54 PMJaguar Animal Health, Inc.
06/10/16 04:54 PMThe Country Caller takes a close look at the pre-market movers for today
06/09/16 04:57 PMU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.11%
06/09/16 04:57 PMTrending: Jaguar Animal Health shares roar after Aspire Capital deal
06/09/16 04:57 PMJaguar Animal Health Skyrockets on Stock Purchase Agreement
06/09/16 04:57 PMJaguar Animal Health (JAGX) Spikes after Becoming Aspire Capital’s Latest Conquest
06/09/16 04:57 PMJaguar Animal Health (JAGX) Enters $15M Common Stock Purchase Agreement with Aspire Capital Fund, LLC
06/09/16 11:06 AMHere's Why Jaguar Animal Health (JAGX) Stock Has Skyrocketed 115% Today -
06/09/16 09:05 AMJaguar Animal Health (JAGX) Stock Surging on Aspire Capital Agreement -
06/09/16 07:27 AMJaguar Animal Health inks $15M stock purchase deal with Aspire Capital; discussing merger with Napo Pharma
06/09/16 05:49 AMJaguar Animal Health Announces $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC - [at noodls] - SAN FRANCISCO--(BUSINESS WIRE)--Jun. 9, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company'), an animal health company focused on developing and commercializing first-in-class gastrointestinal ...
06/06/16 11:12 AMJaguar Animal Health, Inc. :JAGX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 -
05/13/16 02:00 PMBroker Roundup For Jaguar Animal Health, Inc. (JAGX) - Share Trading News - Broker Roundup For Jaguar Animal Health, Inc. (JAGX)Share Trading News08/27/2015 – Feltl & Co. began new coverage on Jaguar Animal Health, Inc. giving the company a “strong-buy” rating. The share price of Jaguar Animal Health, Inc. (JAGX) was up +0.33% during the last trading session, with a day high of 1.67. 5660 shares ...Jaguar Animal Health Incorporated (NASDAQ:JAGX) Sellers Covered 26.09% of Their ShortsB.O.D.Y Confidentialall 2 news articles »
05/10/16 03:30 PMJAGUAR ANIMAL HEALTH, INC. Files SEC form 10-Q, Quarterly Report -
05/07/16 01:52 PMJaguar Animal Health Incorporated (NASDAQ:JAGX) Shorts Decreased by 26.09% After Short Covering - B.O.D.Y Confidential - Jaguar Animal Health Incorporated (NASDAQ:JAGX) Shorts Decreased by 26.09% After Short CoveringB.O.D.Y ConfidentialThe short interest to Jaguar Animal Health Incorporated's float is 0.4%. The stock decreased 6.04% or $0.11 on May 6, hitting $1.71. About 9,285 shares traded hands or 0.02% up from the average. Jaguar Animal Health Inc (NASDAQ:JAGX) has declined ...
05/07/16 01:52 PMJAGUAR ANIMAL HEALTH, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Item 7.01 Regulation FD Disclosure. On May 5, 2016, Jaguar Animal Health, Inc. (the "Company") expects to make a presentation concerning its business to investors and other interested parties (the "Investor Presentation"). A copy of the Investor ...
05/05/16 07:31 AMJAGUAR ANIMAL HEALTH, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
05/04/16 01:49 PMJaguar Animal Health (JAGX) Initiates Dose Determination Study with Target Commercial Paste Formulation of SB-300 - StreetInsider.com - Jaguar Animal Health (JAGX) Initiates Dose Determination Study with Target Commercial Paste Formulation of SB-300StreetInsider.comJaguar Animal Health, Inc. (NASDAQ: JAGX) announced today that it has initiated a dose determination study of the target commercial paste formulation of SB-300, the Company's drug product candidate for the treatment of Equine Gastric Ulcer Syndrome ...Jaguar Animal Health Inc (JAGX) Downgraded to Sell at Zacks Investment ResearchWeb Breaking Newsall 2 news articles »
05/04/16 08:20 AMJaguar Animal Health Initiates Dose Determination Study with the Target Commercial Paste Formulation of SB-300, the Company’s Drug Product Candidate for Treatment of Equine Gastric Ulcer Syndrome - [at noodls] - SAN FRANCISCO--(BUSINESS WIRE)--May 4, 2016-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) ('Jaguar' or the 'Company'), an animal health company focused on developing and commercializing first-in-class gastrointestinal ...
04/28/16 01:58 PMLatest Analyst Ratings For Jaguar Animal Health, Inc. (JAGX) - Share Trading News - Latest Analyst Ratings For Jaguar Animal Health, Inc. (JAGX)Share Trading NewsJaguar Animal Health, Inc. has a 50 day moving average of 1.57 and a 200 day moving average of 2.15. The stock's market capitalization is 13.65M, it has a 52-week low of 1.35 and a 52-week high of 7.06. The share price of the company (JAGX) was up ...
04/27/16 05:04 AMJAGUAR ANIMAL HEALTH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Finan -
04/24/16 01:35 PMAfter Last Week What Do Analysts Think Of Jaguar Animal Health, Inc. (JAGX) - Share Trading News - After Last Week What Do Analysts Think Of Jaguar Animal Health, Inc. (JAGX)Share Trading News08/27/2015 – Feltl & Co. began new coverage on Jaguar Animal Health, Inc. giving the company a “strong-buy” rating. The share price of Jaguar Animal Health, Inc. (JAGX) was down -0.68% during the last trading session, with a day high of 1.51. 5636 ...
04/23/16 02:02 PMHot Alert: Yum! Brands, Inc. (NYSE:YUM), Jaguar Animal Health, Inc. (NASDAQ:JAGX), ViaSat Inc. (NASDAQ:VSAT ... - KC Register - Hot Alert: Yum! Brands, Inc. (NYSE:YUM), Jaguar Animal Health, Inc. (NASDAQ:JAGX), ViaSat Inc. (NASDAQ:VSAT ...KC RegisterJaguar Animal Health, Inc. (NASDAQ:JAGX) announced that standard drug testing in race horses having received SB-300 did not detect any substances commonly disallowed by horse racing authorities. The testing was conducted by an accredited US testing ...and more »
04/19/16 08:15 AMSB-300, Jaguar’s Drug Product Candidate for the Treatment of Gastric Ulcers, Enables Continued Therapy in Performance Horses in Accordance with Standard Testing Guidelines - [at noodls] - Results of Initial Study Show that Jaguar's Equine Product Candidate for Treatment of Gastric Ulcers May Offer Horse Owners an Additional Advantage in the Competition Horse World, where Requirements Exist ...
04/16/16 01:44 PMJaguar Animal Health receives protocol concurrence from US FDA for Canalevia to treat acute diarrhea in dogs - Jaguar Animal Health, Inc., an animal health company focused on developing and commercialising first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, announced that it has obtained protocol concurrence ...
04/13/16 08:14 AMJaguar Animal Health Obtains Protocol Concurrence From FDA for Canalevia Drug Product Candidate for Treatment of Acute Diarrhea in Dogs - [at noodls] - SAN FRANCISCO--(BUSINESS WIRE)--Apr. 13, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company'), an animal health company focused on developing and commercializing first-in-class gastrointestinal ...
04/12/16 02:03 PMBroker Outlook For The Week Ahead Jaguar Animal Health, Inc. (JAGX) - Share Trading News - Broker Outlook For The Week Ahead Jaguar Animal Health, Inc. (JAGX)Share Trading NewsRecently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of Jaguar Animal Health, Inc. (JAGX). The most recent broker reports which have been released note that 0 analysts have ...
04/12/16 02:03 PMSales Of $97.4 Is Expected For Jaguar Animal Health, Inc. (NASDAQ:JAGX) - RealistInvestor.com - Sales Of $97.4 Is Expected For Jaguar Animal Health, Inc. (NASDAQ:JAGX)RealistInvestor.comThe mean of the annual revenue estimate of Jaguar Animal Health, Inc. (NASDAQ:JAGX) is $97.4 and the median is $97.4 as anticipated by 1 analysts for the period ended 4. The highest estimate is set at $97.4 while lowest projection stands at $97.4.
04/06/16 01:57 PMForm 8-K Jaguar Animal Health, For: Apr 01 - San Francisco, CA (April 6, 2016): Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production ...
04/06/16 08:20 AMJaguar Animal Health Appoints John Micek III to Board of Directors - [at noodls] - SAN FRANCISCO--(BUSINESS WIRE)--Apr. 6, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company'), an animal health company focused on developing and commercializing first-in-class gastrointestinal ...
04/04/16 01:38 PMJaguar Animal Health, Inc. (JAGX) Updated Analyst Coverage - Risers & Fallers - Jaguar Animal Health, Inc. (JAGX) Updated Analyst CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of Jaguar Animal Health, Inc. (JAGX). According to the latest broker reports outstanding on Monday 4th of April, 0 analysts have a rating of “strong buy”, 2 analysts ...
04/04/16 01:38 PMJaguar Animal Health, Inc. (JAGX) Updated Analyst Coverage - Risers & Fallers - Jaguar Animal Health, Inc. (JAGX) Updated Analyst CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of Jaguar Animal Health, Inc. (JAGX). According to the latest broker reports outstanding on Monday 4th of April, 0 analysts have a rating of “strong buy”, 2 analysts ...
04/02/16 12:04 PMJAGUAR ANIMAL HEALTH, INC. Financials -
03/29/16 03:16 PMJAGUAR ANIMAL HEALTH, INC. Files SEC form 10-K, Annual Report -
03/25/16 01:43 PMChanges To Broker Targets On Jaguar Animal Health, Inc. (JAGX) - Share Trading News - Changes To Broker Targets On Jaguar Animal Health, Inc. (JAGX)Share Trading NewsRecently some investment brokers have made changes to their outstanding price targets on shares of Jaguar Animal Health, Inc. (JAGX). According to data from Reuters, 1 analyst has a rating of “buy”, 1 analysts “outperform”, 0 analysts “hold”, 0 ...

Social

About Jaguar Animal Health

Jaguar Animal Health logoJaguar Animal Health, Inc. is an animal health company focused on developing and commercializing gastrointestinal products for companion and production animals, and horses. The Company is developing a pipeline of prescription drug product candidates and non-prescription (non-drug) products. Its pipeline includes prescription drug product candidates for over eight indications across various species and non-prescription products targeting over seven species. Its product candidates include Canalevia, Species-specific formulations of crofelemer, Virend (topical), Species-specific formulations of NP-500, Neonorm Calf and Species-specific formulations of Neonorm. Canalevia is its lead prescription drug product candidate for the treatment of various forms of diarrhea in dogs. Neonorm is its lead non-prescription product to support gut health thereby normalizing fecal formation in animals suffering from watery diarrhea, or scours. Its Neonorm operates under Neonorm Calf and Neonorm Foal.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: JAGX
  • CUSIP:
Key Metrics:
  • Previous Close: $1.92
  • 50 Day Moving Average: $1.86
  • 200 Day Moving Average: $1.86
  • P/E Ratio: N/A
  • P/E Growth: -0.03
  • Market Cap: $19.47M
  • Beta: -0.34
  • Current Year EPS Consensus Estimate: $-1.58 EPS
  • Next Year EPS Consensus Estimate: $-0.97 EPS
Additional Links:
Jaguar Animal Health (NASDAQ:JAGX) Chart for Tuesday, July, 26, 2016